13F Holdings
中文EN

PRQR ProQR Therapeutics N.V. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1612940 · Reporting currency EUR · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-15.9%
TTM net income YoY-51.9%
TTM EPS YoY-25.0%
Revenue 3-yr CAGR64.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-273.1%
Net margin-265.2%
FCF margin-338.3%
EBITDA margin—

Returns

ROE-61.2%
ROA-30.1%
ROIC (approx.)—
Asset turnover0.11x

Leverage & solvency

Liabilities / assets56.2%
Debt / equity0.00x
Current ratio3.09x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.25x
Accruals ratio7.6%
Payout ratio—
Capex / revenue6.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: EUR FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue15.91M18.91M6.51M3.59M1.33M
R&D expense44.73M36.36M25.15M50.87M42.22M
SG&A expense15.06M13.66M16.24M18.65M17.37M
Operating income-43.45M-30.47M-31.86M-65.16M-57.21M
Interest expense929,0001.08M1.20M5.13M3.40M
Pretax income-42.16M-27.96M-27.81M-64.11M-60.68M
Income tax19,000-197,000-78,00096,000117,000
Net income-42.18M-27.76M-28.12M-64.42M-60.74M
EBITDA————-54.88M
EPS (basic)-0.40-0.32-0.35-0.90-0.95
EPS (diluted)-0.40-0.32-0.35-0.90-0.95
Weighted avg. shares (diluted)105.33M86.09M81.01M71.64M—
Balance sheet
Cash & equivalents92.41M149.41M118.92M94.78M187.52M
Receivables6.80M3.75M—56.25M—
Current assets100.13M153.84M120.99M154.46M191.48M
PP&E, netmay include right-of-use assets (IFRS)12.63M14.11M16.90M16.24M17.47M
Total assets112.76M167.96M137.88M171.32M209.58M
Current liabilities32.44M38.90M34.20M20.99M27.60M
Short-term debt4.87M4.58M—2.50M4.77M
Long-term debt——4.29M4.27M39.32M
Total debt——4.29M6.77M44.09M
Total liabilities63.38M79.40M96.49M104.64M96.35M
Shareholders' equity49.37M88.56M41.39M67.06M113.83M
Net debt——-114.63M-88.00M-143.43M
Cash flow statement
Operating cash flow-52.79M-36.39M21.55M-68.51M-26.01M
Capital expenditure1.02M1.42M1.37M708,000484,000
Free cash flow-53.81M-37.81M20.18M-69.22M-26.50M
Investing cash flow-1.02M-4.07M4.28M-702,000-425,000
Financing cash flow-1.84M70.28M-2.27M-30.89M136.83M
Depreciation & amortization————2.33M
Stock-based compensation4.01M2.54M3.11M2.87M6.22M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.